Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Healthy Subjects
Interventions: Ziresovir, Placebo; Drug · Other
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Zinc, Placebos for zinc and nicotinamide riboside, Nicotinamide riboside; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: ADHD
Interventions: Placebo, 200mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Dothan, Alabama • Orange, California • Hialeah, Florida + 9 more

Conditions: Pain
Interventions: Acupuncture; Other
Lead sponsor: Allina Health System; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions: patisiran; Drug
Lead sponsor: Austin Neuromuscular Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Lupus
Interventions: Prasterone (GL701); Drug
Lead sponsor: Genelabs Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more

Conditions: Family-centered Care in Pediatric Resuscitation
Interventions: FACETS: Pediatric Resuscitation, Control; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 547 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: New Haven, Connecticut • Philadelphia, Pennsylvania

Conditions: Placenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid
Interventions: Tranexamic Acid, Placebo Drug; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fresno, California

Conditions: Ischemic Heart Disease, Non-ischemic Cardiomyopathy
Interventions: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Placebo; Biological · Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Obesity
Interventions: K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, Matching placebo to K-757 and matching placebo to K-833; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: San Diego, California • Stockbridge, Georgia • Topeka, Kansas + 19 more

Conditions: Low Back Pain
Interventions: Placebo to Week 16; tanezumab 5mg SC, Placebo to Week 16, tanezumab 10 mg SC, Tanezumab 5 mg SC, Tanezumab 10 mg SC, Tramadol PR oral; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,832 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 179
States / cities: Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 124 more

Conditions: Smoking Cessation
Interventions: placebo, Varenicline Tartarate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Crohn's Disease
Interventions: Enhanced Treatment Algorithm, Conventional Step-care Algorithm; Other
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Urbana, Illinois • Shreveport, Louisiana + 2 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Inflammatory Bowel Diseases, Colitis, Ulcerative
Interventions: MORF-057, Placebo; Drug
Lead sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Sun City, Arizona • Lancaster, California • Los Angeles, California + 5 more

Conditions: Tuberculosis, Tuberculosis, Pulmonary
Interventions: TBA-7371, Placebo; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pain Management
Interventions: Bupivacaine/Epinephrine, Saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Huntington Disease
Interventions: physical activity; Behavioral
Lead sponsor: Cardiff University; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Endometriosis
Interventions: Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 188
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more

Conditions: Diabetic Foot Ulcers
Interventions: V.A.C. Negative Pressure Wound Therapy System; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: New Haven, Connecticut • South Miami, Florida • Bethlehem, Pennsylvania + 2 more

Conditions: Insomnia, Depressive Disorder, Major
Interventions: Eszopiclone, Placebo; Drug · Other
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 65
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 62 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more

Conditions: Multiple Myeloma
Interventions: Structural Image, Functional Image, Digit Span subtest, Brief Test of Attention, Trail Making Test (Parts A & B), Auditory Consonant Trigrams Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, The Center for Epidemiological Study-Depression, The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4, Blood draw; Diagnostic Test · Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Rosacea
Interventions: Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1%, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 865 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hawthorne, New York

Search by objective public record fields.

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

Acupuncture in the Emergency Department

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

Evaluation of Online Training Tools in Pediatric Resuscitation

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

A Phase 3 Study of Tanezumab for Chronic Low Back Pain

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

Local Anesthesia for Facial Fractures

PHysical Activity and Exercise Outcomes in Huntington's Disease

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

RSV-F Vaccine Dose Ranging Study in Young Women

Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation

A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.